Sandra J Casak Selected Research

Cyclophosphamide (Cytoxan)

1/2011

U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sandra J Casak Research Topics

Disease

5	Fatigue 11/2023 - 01/2021
5	Diarrhea 11/2023 - 01/2021
4	Nausea 11/2023 - 01/2021
4	Asthenia 12/2022 - 01/2021
2	Abdominal Pain (Pain, Abdominal) 11/2023 - 01/2022
2	Exanthema (Rash) 11/2023 - 12/2022
2	Colorectal Neoplasms (Colorectal Cancer) 11/2023 - 01/2021
2	Cholangiocarcinoma 10/2023 - 01/2022
2	Neoplasms (Cancer) 12/2022 - 02/2002
2	Cough 12/2022 - 01/2022
2	Retinoblastoma (Glioblastoma, Retinal) 05/2005 - 03/2004
1	Fever (Fevers) 11/2023
1	Toxic Optic Neuropathy 10/2023
1	Dry Eye Syndromes (Dry Eye Syndrome) 10/2023
1	Hyperphosphatemia 10/2023
1	Keratitis 10/2023
1	Musculoskeletal Pain 12/2022
1	Disease Progression 01/2022
1	Ascites 01/2022
1	Vomiting 01/2022
1	Proteinuria 01/2021
1	Hepatocellular Carcinoma (Hepatoma) 01/2021
1	Hemorrhage 01/2021
1	Varicose Veins (Varicose Vein) 01/2021
1	Microsatellite Instability 01/2021
1	Hypertension (High Blood Pressure) 01/2021
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2018
1	Stomach Neoplasms (Stomach Cancer) 08/2015
1	Adenocarcinoma 08/2015
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2011

Drug/Important Bio-Agent (IBA)

2	Bevacizumab (Avastin)FDA Link 01/2021 - 01/2018
1	tucatinibIBA 11/2023
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 11/2023
1	Irinotecan (Camptosar)FDA LinkGeneric 11/2023
1	Trastuzumab (Herceptin)FDA Link 11/2023
1	futibatinibIBA 10/2023
1	Retinaldehyde (Retinal)IBA 10/2023
1	NivolumabIBA 12/2022
1	ivosidenibIBA 01/2022
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2022
1	Sorafenib (BAY 43-9006)FDA Link 01/2021
1	atezolizumabIBA 01/2021
1	pembrolizumabIBA 01/2021
1	Biosimilar PharmaceuticalsIBA 01/2018
1	Paclitaxel (Taxol)FDA LinkGeneric 08/2015
1	RamucirumabIBA 08/2015
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2011
1	Rituximab (Mabthera)FDA Link 01/2011
1	fludarabineIBA 01/2011
1	Topotecan (Hycamtin)FDA LinkGeneric 03/2004

Therapy/Procedure

4	Therapeutics 01/2022 - 02/2002
3	Drug Therapy (Chemotherapy) 11/2023 - 01/2022
1	Chemoradiotherapy 12/2022